Relay Therapeutics, Inc.
RLAY
Rangering i aksjer
#4396
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Aksjekurs
$16.24
Sist synkronisert: 2026-10-16
Markedsverdi
$3.56B
Endring (1 dag)
-6.13%
Endring (1 år)
150.23%
Land
US
Handel Relay Therapeutics, Inc. (RLAY)
Kategori
Healthcare
Driftsmargin for Relay Therapeutics, Inc. (RLAY)
Driftsmargin per October 2026 TTM: -2,999.38%
Ifølge Relay Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) -2,999.38%. Ved slutten av 2023 hadde selskapet en driftsmargin på -1,460.11%.
Historikk for driftsmargin for Relay Therapeutics, Inc. fra 2018 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | -2,999.38% | -19.42% |
| 2024 | -3,722.07% | 154.92% |
| 2023 | -1,460.11% | -93.26% |
| 2022 | -21,670.89% | 79.99% |
| 2021 | -12,040.21% | 17,734.71% |
| 2020 | -67.51% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -100.01% |
US
|
|
| -149.01% | -99.95% |
US
|
|
| 25.57% | -100.01% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.01% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.